LBF20406AM42: Difference between revisions
m (LBF20806AM01 moved to LBF20406AM42) |
No edit summary |
||
(18 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
{{Lipid/Header}} | |||
{{Hierarchy|{{PAGENAME}}}} | {{Hierarchy|{{PAGENAME}}}} | ||
{{Metabolite | {{Metabolite | ||
|LipidBank=XPR7044 | |LipidBank=XPR7044 | ||
|LipidMaps=LMFA08020030 | |LipidMaps=LMFA08020030 | ||
|SysName= | |SysName=dl-N- (1-Methyl-2-hydroxy-2-phenylethyl) - (cis-5,cis-8,cis-11,cis-14) -eicosatetraenoylamine | ||
|Common Name=&&(+-) -N- (1- | |Common Name=&&N- (1-Methyl-2-hydroxy-2-phenylethyl) -arachidonoylamide&&(+-) -N- (1-Methyl-2-hydroxy-2-phenylethyl) - (5Z,8Z,11Z,14Z) -eicosatetraenoylamine&& | ||
|Melting Point=colorless oil [[Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659|{{RelationTable/GetFirstAuthor|Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659}}]] | |Melting Point=colorless oil [[Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659|{{RelationTable/GetFirstAuthor|Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659}}]] | ||
|NMR Spectra= | |NMR Spectra=^1 H NMR (CDCl3) delta 7.27-7.35 (m, 5H), 5.54 (br s , lH), 5.63-5.41 (m, 8H), 4.84 (br s, lH),4.31-4.36 (m, lH), 3.60 (br s, lH), 2.78-2.85 (m, 6H), 2.01-2.22 (m, 6H), 1.67-1.77 (m, 2H),1.25-1.37 (m, 6H), 1.01 (d, J=7.l Hz, 3H), 0.89 (t, J=7.l Hz, 3H). [[Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659|{{RelationTable/GetFirstAuthor|Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659}}]] | ||
|Source= | |||
|Chemical Synthesis=This compound was synthesized from arachidonoylchloride and (±)phenylpropanolamine.Yield 67 %. [[Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659|{{RelationTable/GetFirstAuthor|Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659}}]] | |||
|Metabolism= | |||
|Biological Activity=Binding to the brain cannabinoid receptor (CBl), Ki(nM)>1000 [[Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659|{{RelationTable/GetFirstAuthor|Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659}}]] | |||
}} | }} | ||
{{Lipid/Footer}} | {{Lipid/Footer}} |
Latest revision as of 04:50, 21 October 2010
LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
IDs and Links | |
---|---|
LipidBank | XPR7044 |
LipidMaps | LMFA08020030 |
CAS | |
KEGG | {{{KEGG}}} |
KNApSAcK | {{{KNApSAcK}}} |
mol | LBF20406AM42 |
N- (1-Methyl-2-hydroxy-2-phenylethyl) -arachidonoylamide | |
---|---|
Structural Information | |
dl-N- (1-Methyl-2-hydroxy-2-phenylethyl) - (cis-5,cis-8,cis-11,cis-14) -eicosatetraenoylamine | |
| |
Formula | C29H43NO2 |
Exact Mass | 437.329379625 |
Average Mass | 437.65725999999995 |
SMILES | C(=CCC=CCC=CCCCC(=O)NC(C(O)c(c1)cccc1)C)CC=CCCCCC |
Physicochemical Information | |
colorless oil Sheskin_T et al. | |
This compound was synthesized from arachidonoylchloride and (±)phenylpropanolamine.Yield 67 %. Sheskin_T et al. | |
Binding to the brain cannabinoid receptor (CBl), Ki(nM)>1000 Sheskin_T et al. | |
Spectral Information | |
Mass Spectra | |
UV Spectra | |
IR Spectra | |
NMR Spectra | 1H NMR (CDCl3) δ 7.27-7.35 (m, 5H), 5.54 (br s , lH), 5.63-5.41 (m, 8H), 4.84 (br s, lH),4.31-4.36 (m, lH), 3.60 (br s, lH), 2.78-2.85 (m, 6H), 2.01-2.22 (m, 6H), 1.67-1.77 (m, 2H),1.25-1.37 (m, 6H), 1.01 (d, J=7.l Hz, 3H), 0.89 (t, J=7.l Hz, 3H). SheskinTet al. |
Other Spectra | |
Chromatograms |
Reported Metabolites, References | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
|